BIOMAT Database Logo BIOMAT Database Logo

Randomised controlled trial of lymphoblastoid interferon for chronic active hepatitis B. 1986

M G Anderson, and T J Harrison, and G J Alexander, and A J Zuckerman, and I M Murray-Lyon

Thirty male patients (28 homosexual or bisexual) with biopsy proven chronic active hepatitis B were randomised to receive lymphoblastoid interferon (Wellferon) or no treatment. All patients were HBeAg-positive and had continuing viral replication. Interferon was given as a single daily i.m. injection for 28 days at a starting dose of 2.5 megaunits/m2 increasing to a maximum of 7.5 megaunits/m2/day. Transient side-effects occurred in all patients. Hepatitis B viral replication was suppressed during interferon treatment in all patients but the effect was limited to the period of therapy. After 1 year there was no appreciable difference in viral markers between the two groups of patients and this treatment schedule appears less effective than the thrice weekly, 3-month regimes reported from other centres.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D008297 Male Males
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006515 Hepatitis B virus The type species of the genus ORTHOHEPADNAVIRUS which causes human HEPATITIS B and is also apparently a causal agent in human HEPATOCELLULAR CARCINOMA. The Dane particle is an intact hepatitis virion, named after its discoverer. Non-infectious spherical and tubular particles are also seen in the serum. Dane Particle,Hepatitis Virus, Homologous Serum,B virus, Hepatitis,Hepatitis B viruses,Particle, Dane,viruses, Hepatitis B
D006521 Hepatitis, Chronic INFLAMMATION of the LIVER with ongoing hepatocellular injury for 6 months or more, characterized by NECROSIS of HEPATOCYTES and inflammatory cell (LEUKOCYTES) infiltration. Chronic hepatitis can be caused by viruses, medications, autoimmune diseases, and other unknown factors. Chronic Hepatitis,Cryptogenic Chronic Hepatitis,Hepatitis, Chronic, Cryptogenic,Hepatitis, Chronic Active,Hepatitis, Chronic Persistent,Chronic Active Hepatitis,Chronic Hepatitis, Cryptogenic,Chronic Persistent Hepatitides,Chronic Persistent Hepatitis,Hepatitis, Cryptogenic Chronic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications

Related Publications

M G Anderson, and T J Harrison, and G J Alexander, and A J Zuckerman, and I M Murray-Lyon
Randomised controlled trial of interferon alfa (lymphoblastoid interferon) in chronic non-A non-B hepatitis.
January 1989, BMJ (Clinical research ed.),
M G Anderson, and T J Harrison, and G J Alexander, and A J Zuckerman, and I M Murray-Lyon
Randomised controlled trial of recombinant human interferon -alpha A for chronic active hepatitis B.
February 1990, Australian and New Zealand journal of medicine,
M G Anderson, and T J Harrison, and G J Alexander, and A J Zuckerman, and I M Murray-Lyon
Randomised controlled trial of lymphoblastoid interferon alfa in Europid men with chronic hepatitis B virus infection.
September 1989, BMJ (Clinical research ed.),
M G Anderson, and T J Harrison, and G J Alexander, and A J Zuckerman, and I M Murray-Lyon
Human lymphoblastoid interferon for the treatment of chronic hepatitis B. A randomized controlled trial.
August 1988, The American journal of medicine,
M G Anderson, and T J Harrison, and G J Alexander, and A J Zuckerman, and I M Murray-Lyon
A controlled trial of human lymphoblastoid interferon in chronic hepatitis B in Italy.
September 1989, Hepatology (Baltimore, Md.),
M G Anderson, and T J Harrison, and G J Alexander, and A J Zuckerman, and I M Murray-Lyon
Treatment of chronic hepatitis B with human lymphoblastoid interferon: results of a controlled trial.
December 1988, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,
M G Anderson, and T J Harrison, and G J Alexander, and A J Zuckerman, and I M Murray-Lyon
Treatment of chronic hepatitis B with human lymphoblastoid interferon: results of a controlled trial.
July 1989, Journal of chemotherapy (Florence, Italy),
M G Anderson, and T J Harrison, and G J Alexander, and A J Zuckerman, and I M Murray-Lyon
A randomised controlled trial with human lymphoblastoid interferon vs no treatment in chronic hepatitis B virus infection. Preliminary results.
January 1986, Journal of hepatology,
M G Anderson, and T J Harrison, and G J Alexander, and A J Zuckerman, and I M Murray-Lyon
Randomized controlled clinical trial of lymphoblastoid interferon-alpha for chronic hepatitis C.
September 2001, Hepatology research : the official journal of the Japan Society of Hepatology,
M G Anderson, and T J Harrison, and G J Alexander, and A J Zuckerman, and I M Murray-Lyon
Lymphoblastoid interferon in controlled trials of chronic hepatitis B virus infection.
January 1988, Hepatology (Baltimore, Md.),
Copied contents to your clipboard!